| Not Yet Recruiting | Understanding MPXV Viral Clearance, Transmission Dynamics, and Mpox Vaccine Effectiveness in West Africa : Gui NCT07534267 | London School of Hygiene and Tropical Medicine | — |
| Recruiting | Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BSY001 After Single/Multiple Doses. NCT07377175 | China National Biotec Group Company Limited | Phase 1 |
| Recruiting | Evaluation of Long-term Immunogenicity of a Boost Dose of MVA-BN Vaccine NCT06885853 | Assistance Publique - Hôpitaux de Paris | — |
| Recruiting | A Study Evaluating the Safety and Immunogenicity of MVA Strain Monkeypox Attenuated Live Vaccine NCT06771479 | Shanghai Institute Of Biological Products | Phase 1 |
| Completed | Ocular Complications of Mpox in the Democratic Republic Congo NCT06579885 | Institute of Tropical Medicine, Belgium | — |
| Recruiting | Smallpox Vaccine for Mpox Post-Exposure Prophylaxis: A Cluster RCT NCT05745987 | McMaster University | Phase 4 |
| Recruiting | European Trial Into Mpox Infection NCT06156566 | Miquel Ekkelenkamp | Phase 4 |
| Recruiting | Observational, Prospective, Cohort Study of Mpox Infection in Brazil (NETPOX) NCT05784038 | Hospital Israelita Albert Einstein | — |
| Active Not Recruiting | Efficacy/Effectiveness, Safety, and Immunogenicity of LC16m8 Mpox Vaccine in Colombia NCT06223919 | Universidad Nacional de Colombia | Phase 3 |
| Completed | Morbidity, Mortality And Risk Factors of Mpox in HIV Negative High Risk Sexual Health Clinic Attenders and Peo NCT05965427 | NEAT ID Foundation | — |
| Completed | A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigational Monkeyp NCT05988203 | BioNTech SE | Phase 1 / Phase 2 |
| Suspended | Tecovirimat in Non-hospitalized Patients With Monkeypox NCT05534165 | Marina Klein | Phase 3 |
| Completed | Assessment of Safety Profile of MVA-BN Vaccine in the PALM-007 Study in DRC NCT05734508 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 4 |
| Completed | A Phase 2 Randomized Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine fo NCT05740982 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Recruiting | Virologic and Immunologic Characteristics of Severe Mpox in Persons With Advanced HIV NCT06045923 | Centers for Disease Control and Prevention | — |
| Unknown | Mpox Paediatric and Adolescent Clinical Study NCT05947786 | PENTA Foundation | — |
| Recruiting | Assessment of the Efficacy and Safety of Tecovirimat in Patients With Monkeypox Virus Disease NCT05597735 | ANRS, Emerging Infectious Diseases | Phase 3 |
| Enrolling By Invitation | New York City Observational Study of Mpox Immunity NCT05654883 | NYU Langone Health | — |
| Unknown | Pilot Study to Detect Monkey Pox Virus in Sperm: POXSPERM NCT05629299 | University Hospital, Toulouse | N/A |
| Completed | Tecovirimat for Treatment of Monkeypox Virus NCT05559099 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Recruiting | Prospective Study for the FOLLOW-UP of Human Monkeypox Cases and Smallpox Vaccinees at Risk NCT05879965 | Institute of Tropical Medicine, Belgium | — |
| Terminated | Clinical, Virological, Immunological, Psychosocial and Epidemiological Consequences of Human Monkeypox Virus ( NCT05567939 | Public Health Service of Amsterdam | — |
| Recruiting | Characterization of Vaccine-induced Responses Against Monkeypox (MoVIHvax) An Observational Prospective Cohort NCT05562323 | Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia | — |
| Completed | Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Monkeypox Vaccine NCT05512949 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Completed | Viral Clearance and Epidemiological Characteristics in Patients With Monkeypox NCT05476744 | Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia | — |
| Unknown | Mpox Prospective Observational Cohort Study NCT06291259 | Unity Health Toronto | — |
| Completed | Study on Immunogenicity, Reactogenicity and Safety of the VACΔ6 Vaccine in Volunteers Aged 18-60 Years NCT05846243 | Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector" | Phase 2 / Phase 3 |
| Completed | Study of the Safety, Tolerability, Pharmacokinetics of NIOCH-14 in Volunteers Aged 18-50 Years NCT05976100 | Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector" | Phase 1 |
| Completed | Safety and Tolerability Study of the VAC∆6 Vaccine in Volunteers Aged 18-40 Years NCT05762523 | Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector" | Phase 1 |
| Completed | Cohort Study of Healthcare Workers Receiving Imvanex® NCT03745131 | Public Health England | — |
| Available | Tecovirimat (ST-246) Treatment for Orthopox Virus Exposure NCT02080767 | U.S. Army Medical Research and Development Command | — |